Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897733689> ?p ?o ?g. }
- W2897733689 endingPage "168" @default.
- W2897733689 startingPage "160" @default.
- W2897733689 abstract "Talazoparib (1 mg/day) exhibited promising efficacy and safety in patients with advanced breast cancer during ABRAZO (NCT02034916); this study evaluated patient-reported outcomes (PROs).ABRAZO is a two-cohort, two-stage, phase 2 study of talazoparib in patients with advanced breast cancer after a response to prior platinum-based therapy (cohort 1 [C1], n = 49) or ≥3 platinum-free cytotoxic-based regimens (cohort 2 [C2], n = 35). PROs were assessed on day 1 (baseline), every 6 weeks for an initial 24 weeks, and every 12 weeks thereafter until progression, using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) and its breast cancer module, QLQ-BR23.Global health status/quality of life (GHS/QoL) was maintained from baseline across all time points for both C1 and C2. For C1 and C2, median time to deterioration (TTD) of GHS/QoL (95% confidence interval [CI]) was 2.8 (2.1, 3.0) and 5.5 (4.2, 5.7) months, respectively. Median TTD for all QLQ-C30 functional scales for C1 and C2 ranged 2.1-3.1 months and 4.2-5.6 months, respectively; median TTD for all QLQ-BR23 symptom scales ranged 2.6-4.0 months and 4.2-5.6 months, respectively. There were no statistically significant differences in estimated overall change from baseline in the GHS/QoL scale for both cohorts (C1: -2.6 [95% CI, -7.8, 2.5]; C2: 1.2 [95% CI, -5.5, 8.0]). Significant overall improvements in the breast symptoms and arm symptoms and the future perspective of patients in C1 and C2 were observed, despite the statistically significant and clinically meaningful overall deterioration among patients regarding their role functioning (in C1) and dyspnoea symptoms (in C2).Despite the statistically significant and clinically meaningful overall deterioration among patients regarding their role functioning (in C1) and dyspnoea symptoms (in C2), patients in both C1 and C2 reported significant overall improvements in their breast symptoms, arm symptoms and future perspective, and their GHS/QoL was maintained from baseline." @default.
- W2897733689 created "2018-10-26" @default.
- W2897733689 creator A5001731251 @default.
- W2897733689 creator A5013148496 @default.
- W2897733689 creator A5017728105 @default.
- W2897733689 creator A5019071326 @default.
- W2897733689 creator A5040255985 @default.
- W2897733689 creator A5045514288 @default.
- W2897733689 creator A5048706345 @default.
- W2897733689 creator A5052487618 @default.
- W2897733689 creator A5060044961 @default.
- W2897733689 creator A5065272343 @default.
- W2897733689 creator A5068059897 @default.
- W2897733689 creator A5083605021 @default.
- W2897733689 creator A5086049069 @default.
- W2897733689 creator A5089364285 @default.
- W2897733689 creator A5090188675 @default.
- W2897733689 date "2018-11-01" @default.
- W2897733689 modified "2023-09-25" @default.
- W2897733689 title "Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial" @default.
- W2897733689 cites W1481680922 @default.
- W2897733689 cites W1947168884 @default.
- W2897733689 cites W1974191288 @default.
- W2897733689 cites W2020902095 @default.
- W2897733689 cites W2054716402 @default.
- W2897733689 cites W2139269097 @default.
- W2897733689 cites W2167571044 @default.
- W2897733689 cites W2597062310 @default.
- W2897733689 cites W2621271973 @default.
- W2897733689 cites W2753603515 @default.
- W2897733689 cites W2801956643 @default.
- W2897733689 cites W2883009810 @default.
- W2897733689 cites W2883673963 @default.
- W2897733689 cites W2884001607 @default.
- W2897733689 cites W2886477543 @default.
- W2897733689 cites W4239051461 @default.
- W2897733689 doi "https://doi.org/10.1016/j.ejca.2018.09.003" @default.
- W2897733689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30359909" @default.
- W2897733689 hasPublicationYear "2018" @default.
- W2897733689 type Work @default.
- W2897733689 sameAs 2897733689 @default.
- W2897733689 citedByCount "14" @default.
- W2897733689 countsByYear W28977336892018 @default.
- W2897733689 countsByYear W28977336892019 @default.
- W2897733689 countsByYear W28977336892020 @default.
- W2897733689 countsByYear W28977336892021 @default.
- W2897733689 countsByYear W28977336892022 @default.
- W2897733689 countsByYear W28977336892023 @default.
- W2897733689 crossrefType "journal-article" @default.
- W2897733689 hasAuthorship W2897733689A5001731251 @default.
- W2897733689 hasAuthorship W2897733689A5013148496 @default.
- W2897733689 hasAuthorship W2897733689A5017728105 @default.
- W2897733689 hasAuthorship W2897733689A5019071326 @default.
- W2897733689 hasAuthorship W2897733689A5040255985 @default.
- W2897733689 hasAuthorship W2897733689A5045514288 @default.
- W2897733689 hasAuthorship W2897733689A5048706345 @default.
- W2897733689 hasAuthorship W2897733689A5052487618 @default.
- W2897733689 hasAuthorship W2897733689A5060044961 @default.
- W2897733689 hasAuthorship W2897733689A5065272343 @default.
- W2897733689 hasAuthorship W2897733689A5068059897 @default.
- W2897733689 hasAuthorship W2897733689A5083605021 @default.
- W2897733689 hasAuthorship W2897733689A5086049069 @default.
- W2897733689 hasAuthorship W2897733689A5089364285 @default.
- W2897733689 hasAuthorship W2897733689A5090188675 @default.
- W2897733689 hasConcept C121608353 @default.
- W2897733689 hasConcept C126322002 @default.
- W2897733689 hasConcept C143998085 @default.
- W2897733689 hasConcept C159110408 @default.
- W2897733689 hasConcept C2779951463 @default.
- W2897733689 hasConcept C44249647 @default.
- W2897733689 hasConcept C530470458 @default.
- W2897733689 hasConcept C71924100 @default.
- W2897733689 hasConcept C72563966 @default.
- W2897733689 hasConceptScore W2897733689C121608353 @default.
- W2897733689 hasConceptScore W2897733689C126322002 @default.
- W2897733689 hasConceptScore W2897733689C143998085 @default.
- W2897733689 hasConceptScore W2897733689C159110408 @default.
- W2897733689 hasConceptScore W2897733689C2779951463 @default.
- W2897733689 hasConceptScore W2897733689C44249647 @default.
- W2897733689 hasConceptScore W2897733689C530470458 @default.
- W2897733689 hasConceptScore W2897733689C71924100 @default.
- W2897733689 hasConceptScore W2897733689C72563966 @default.
- W2897733689 hasLocation W28977336891 @default.
- W2897733689 hasLocation W28977336892 @default.
- W2897733689 hasOpenAccess W2897733689 @default.
- W2897733689 hasPrimaryLocation W28977336891 @default.
- W2897733689 hasRelatedWork W2035682242 @default.
- W2897733689 hasRelatedWork W2071535500 @default.
- W2897733689 hasRelatedWork W2082392604 @default.
- W2897733689 hasRelatedWork W2195671413 @default.
- W2897733689 hasRelatedWork W2276162241 @default.
- W2897733689 hasRelatedWork W2315085516 @default.
- W2897733689 hasRelatedWork W2603773853 @default.
- W2897733689 hasRelatedWork W3112166790 @default.
- W2897733689 hasRelatedWork W377899687 @default.
- W2897733689 hasRelatedWork W4322771458 @default.
- W2897733689 hasVolume "104" @default.
- W2897733689 isParatext "false" @default.